

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Southeast Hospital d/b/a Mercy Hospital Southeast 2. 1701 Lacey St. Cape Girardeau, MO 63701		In accordance with letters dated July 14, 2026, August 25, 2026, and September 14, 2026,	4. Expiration Date: October 31, 2037
		3. License No.: 24-00128-03 is amended in its entirety to read as follows:	5. Docket No.: 030-02264 Reference No.: 030-34136/24-26563-01
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 3 curies total	C. For any use permitted by 10 CFR 35.300.
D. Strontium-90 permitted by 10 CFR 35.400	D. Sealed Sources (Dupont Merck Pharmaceutical Co, Model NB-1)	D. 120 millicuries total	D. For any ophthalmic manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00128-03

Amendment No. 128

Docket or Reference No.:

030-02264

030-34136/24-26563-01

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| E. Yttrium-90 permitted by 10 CFR 35.1000 | E. Microspheres (BWXT Medical Ltd., Model TheraSphere) | E. 540 millicuries per vial and 3 curies total | E. For use in permanent manual brachytherapy using BWXT Medical Ltd. Model TheraSphere Yttrium-90 microspheres and delivery system permitted by 10 CFR 35.1000. |



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00128-03

Amendment No. 128

Docket or Reference No.:

030-02264

030-34136/24-26563-01

CONDITIONS

10. A. Licensed material shall be used and stored at the licensee's facilities located at 1701 Lacey St., Cape Girardeau, Missouri 63701, 817 S. Mt. Auburn Rd., Cape Girardeau, Missouri 63703, and 789 S. Mt. Auburn Rd., Cape Girardeau, Missouri 63703.
- B. Licensed material listed in Item No. 6.B. shall be used and stored at the licensee's facilities located at 371 S. Broadview, Cape Girardeau, Missouri 63703.
- C. Licensed material listed in Item Nos. 6.A. and 6.B. shall be used and stored at the licensee's facilities located at 434 Northwest St., Perryville, Missouri 63775.
11. The Radiation Safety Officer (RSO) for this license is Samuel S. Hancock, Ph.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users and/or authorized medical physicists in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)

Khadrah Mousa Alsomali, M.D.

Matthew Bean, M.D.

Bryan S. Beck, M.D.

James J. Borders, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00128-03

Docket or Reference No.:

030-02264

030-34136/24-26563-01

Amendment No. 128

Authorized User (M.D., D.O., etc.)

Jeffrey W. Boss, M.D.

Todd Michael Buersmeyer, M.D.

Steven J. Carr, M.D.

Thomas Joseph Crocetti, D.O.

Ali Farooq, M.D.

Derek L. Fimmen, M.D.

Mark L. Gates, M.D.

Narendra Babu Gutta, M.D.

Stephen W. Humes, M.D.

Chizor Iwuchukwu, M.D.

Jerry J. Jaboin, M.D.

David A. Law, M.D.

William Lea, M.D.

Evan Mason, D.O.

Shanaree M. Muzinich, M.D.

Huan Luong Nguyen, M.D.

Frank C. Ogbonna, M.D., D.O.

Soraya Ong, M.D.

Mark L. Pfautsch, D.O.

George A. Pjura, M.D.

Munis Raza, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131), 10 CFR 35.1000 (limited to yttrium-90 as TheraSphere)

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.200

10 CFR 35.300; 10 CFR 35.400

10 CFR 35.200

10 CFR 35.1000 (limited to yttrium-90 as TheraSphere)

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00128-03

Amendment No. 128

Docket or Reference No.:

030-02264

030-34136/24-26563-01

Authorized User (M.D., D.O., etc.)

Christopher T. Russell, M.D.

Ryan Siebert, M.D.

Clyde D. Sullivan, M.D.

Theodore R. Swartz, M.D.

Michael Thomas, M.D.

Toms Vengaloor Thomas, M.B., B.S.

Jeffrey Wichman, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.300

10 CFR 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit in 10 CFR 30.35(d) for which decommissioning financial assurance is required.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Letter dated April 26, 2022 (ML22117A061)
- B. Letter dated July 7, 2022 (ML22189A051)
- C. Letter dated July 8, 2022 (ML22189A163)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00128-03

Amendment No. 128

Docket or Reference No.:

030-02264

030-34136/24-26563-01

- D. Letter dated March 9, 2023 (ML23069A020)
E. Letter dated September 1, 2023 (ML23248A350)
F. Letter dated December 21, 2023 (ML23355A205)
G. Letter dated January 24, 2024 (ML24024A223)
H. Letter dated January 20, 2025 (ML25023A198)
I. Letter dated February 21, 2025 (ML25052A252)
J. Letter dated July 3, 2025 (ML25188A073)
K. Letter dated May 13, 2026 with attachments (ML26134A036)

Date: September 21, 2026

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

MAGDALENABy: **GRYGLAK**Digitally signed by MAGDALENA
GRYGLAK

Date: 2026.09.21 09:29:43 -05'00'

Magdalena R. Gryglak
Office of Nuclear Material Safety and Safeguards
Division of Federal Materials Programs
Inspection and Licensing Branch Central